Girl’s death in China reveals human cost of unregulated science
But as the new investigation by Science and Retraction Watch has found, the rifts between what the law says and how it is enforced have remained wide enough for a similar failure to recur.Dr. One emphasised exhaustive reviews before ‘first in human’ use. Another allowed investigator-initiated trials to proceed more rapidly.
- ▪But as the new investigation by Science and Retraction Watch has found, the rifts between what the law says and how it is enforced have remained wide enough for a similar failure to recur.Dr.
- ▪One emphasised exhaustive reviews before ‘first in human’ use.
- ▪Another allowed investigator-initiated trials to proceed more rapidly.
The Hindu publishes from India and files mainly under world. We currently carry 771 of its stories.
Opening excerpt (first ~120 words) tap to expand
A six-year-old girl in China died in March 2025 after receiving what researchers said they believed was the world’s first base-editing therapy directed at the brain, according to an investigation by Science and Retraction Watch.The investigation has raised important questions about the oversight of an experimental personalised gene-editing trial and the way the researchers and their institutions communicated their choices.The girl had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder caused by a mutation in the CHD3 gene.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu.
Discussion
0 commentsMore from The Hindu
